Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy By Ogkologos - February 19, 2026 55 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the marginal zone lymphoma cohort of the TRANSCEND FL study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Nivolumab with Chemotherapy for Previously Untreated Hodgkin Lymphoma 2026 ESMO Breast Cancer Award Recipient Announced Solid Organ Transplant Recipients with Pretransplant Cancer Have an Elevated Risk of Posttransplant Cancer of the Same Cancer Type MOST POPULAR Do Birth Control Pills Impact My Cancer Risk? October 20, 2022 Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for... July 8, 2025 Why it’s difficult to estimate the number of extra cancer deaths... July 21, 2020 Rebuilding My Life After Cancer and Intensive Treatment: A Survivor’s Story February 9, 2023 Load more HOT NEWS Cancer in My Community: Reducing Tobacco Use in Tunisia 10-Year Data Underscore How ICI Therapy Has Helped to Change the... EMA Recommends Extension of Indications for Venetoclax Learning the lessons of COVID-19: Protecting cancer services and research through...
